Efor Expands U.S. CQV Capabilities Through the Addition of Gills Process Control
1/07/2026
We’re continuing to build out our U.S. platform with the addition of Gills Process Control (GPCi), a North Carolina-based specialist in Commissioning, Qualification and Validation. This move strengthens our presence in the U.S. market, where we’re targeting €70 million in revenue in 2026 and aiming to exceed €400 million by 2030. It reflects our growth strategy, combining sustained organic growth with targeted acquisitions, as we work toward becoming the global leader in quality and compliance for the life sciences industry.
Efor group
Our CSR commitments
Aware of our social and environmental responsibility, we act every day to make a positive impact on society.
Our news
Discover all our technical articles and news
-
Technical articles16/07/2026
Validating Cloud & SaaS Solutions in GxP-Regulated Environments: Shared Responsibility, Vendor Qualification, and Continuous Compliance
As more and more healthcare manufacturers adopt these technologies, they must remain particularly vigilant about how this choice a
-
News9/07/2026
Efor launches Valimate, its artificial intelligence platform dedicated to compliance and validation in Life Sciences
Efor Valimate, the new artificial intelligence platform developed by Efor to support CQV professionals.
-
News2/07/2026
Efor and TIME France unveil the first edition of the TIME France Health awards
We are proud to unveil the results of the first edition of the TIME France Health awards, created by TIME France in partnership wi